Gilead Sciences is drawing up $20 million cash to partner with Cartography Biosciences and navigate drug discovery for triple-negative breast cancer and adenocarcinoma, a common form of non-small cell ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely targets tumors, today announced an ...
Financing led by Pfizer Ventures will support advancement of lead program CBI-1214 into a Phase 1 trial, targeted for enrollment in early 2026, and expand next wave of programs from the ATLAS and ...
Cartography Biosciences is putting its name on the map, exiting stealth mode with $57 million for an antigen atlas designed to direct scientists to more precise and effective immunotherapies.
Colorectal cancer patients whose disease exhibits certain rare genetic signatures have the option of treatment with immunotherapies. But these targeted cancer treatments haven’t worked for patients ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., an oncology company advancing an innovative pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback